342 related articles for article (PubMed ID: 35032406)
1. PLGA's Plight and the Role of Stealth Surface Modification Strategies in Its Use for Intravenous Particulate Drug Delivery.
Sheffey VV; Siew EB; Tanner EEL; Eniola-Adefeso O
Adv Healthc Mater; 2022 Apr; 11(8):e2101536. PubMed ID: 35032406
[TBL] [Abstract][Full Text] [Related]
2. Effect of nanoparticle size and PEGylation on the protein corona of PLGA nanoparticles.
Partikel K; Korte R; Stein NC; Mulac D; Herrmann FC; Humpf HU; Langer K
Eur J Pharm Biopharm; 2019 Aug; 141():70-80. PubMed ID: 31082511
[TBL] [Abstract][Full Text] [Related]
3. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats.
Li Y; Pei Y; Zhang X; Gu Z; Zhou Z; Yuan W; Zhou J; Zhu J; Gao X
J Control Release; 2001 Apr; 71(2):203-11. PubMed ID: 11274752
[TBL] [Abstract][Full Text] [Related]
4. Poly(lactic-co-glycolic) Acid (PLGA) Nanoparticles and Transdermal Drug Delivery: An Overview.
Kumar L; Kukreti G; Rana R; Chaurasia H; Sharma A; Sharma N; Komal
Curr Pharm Des; 2023; 29(37):2940-2953. PubMed ID: 38173050
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticles Based on Novel Carbohydrate-Functionalized Polymers.
Raposo CD; Conceição CA; Barros MT
Molecules; 2020 Apr; 25(7):. PubMed ID: 32290160
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile.
Rafiei P; Haddadi A
Int J Nanomedicine; 2017; 12():935-947. PubMed ID: 28184163
[TBL] [Abstract][Full Text] [Related]
7. Progress in the drug encapsulation of poly(lactic-
Dodda JM; Remiš T; Rotimi S; Yeh YC
J Mater Chem B; 2022 Jun; 10(22):4127-4141. PubMed ID: 35593381
[TBL] [Abstract][Full Text] [Related]
8. Micelle-templated, poly(lactic-
Nabar GM; Mahajan KD; Calhoun MA; Duong AD; Souva MS; Xu J; Czeisler C; Puduvalli VK; Otero JJ; Wyslouzil BE; Winter JO
Int J Nanomedicine; 2018; 13():351-366. PubMed ID: 29391794
[TBL] [Abstract][Full Text] [Related]
9. Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery.
Parveen S; Sahoo SK
Eur J Pharmacol; 2011 Nov; 670(2-3):372-83. PubMed ID: 21951969
[TBL] [Abstract][Full Text] [Related]
10. Preferential tumor accumulation and desirable interstitial penetration of poly(lactic-co-glycolic acid) nanoparticles with dual coating of chitosan oligosaccharide and polyethylene glycol-poly(D,L-lactic acid).
Wang G; Chen Y; Wang P; Wang Y; Hong H; Li Y; Qian J; Yuan Y; Yu B; Liu C
Acta Biomater; 2016 Jan; 29():248-260. PubMed ID: 26476340
[TBL] [Abstract][Full Text] [Related]
11. Low molecular-weight chitosan as a pH-sensitive stealth coating for tumor-specific drug delivery.
Amoozgar Z; Park J; Lin Q; Yeo Y
Mol Pharm; 2012 May; 9(5):1262-70. PubMed ID: 22489704
[TBL] [Abstract][Full Text] [Related]
12. Influence of PEGylation on PLGA nanoparticle properties, hydrophobic drug release and interactions with human serum albumin.
Samkange T; D'Souza S; Obikeze K; Dube A
J Pharm Pharmacol; 2019 Oct; 71(10):1497-1507. PubMed ID: 31385295
[TBL] [Abstract][Full Text] [Related]
13. Polydopamine-based surface modification for the development of peritumorally activatable nanoparticles.
Gullotti E; Park J; Yeo Y
Pharm Res; 2013 Aug; 30(8):1956-67. PubMed ID: 23609560
[TBL] [Abstract][Full Text] [Related]
14. Biodegradable self-assembled nanoparticles of PEG-PLGA amphiphilic diblock copolymer as a promising stealth system for augmented vinpocetine brain delivery.
Ahmed OAA; Badr-Eldin SM
Int J Pharm; 2020 Oct; 588():119778. PubMed ID: 32805381
[TBL] [Abstract][Full Text] [Related]
15. Microfluidic Manufacturing of Multitargeted PLGA/PEG Nanoparticles for Delivery of Taxane Chemotherapeutics.
Martins C; Sarmento B
Methods Mol Biol; 2020; 2059():213-224. PubMed ID: 31435924
[TBL] [Abstract][Full Text] [Related]
16. Anti-EGFR-mAb and 5-Fluorouracil Conjugated Polymeric Nanoparticles for Colorectal Cancer.
Bhattacharya S
Recent Pat Anticancer Drug Discov; 2021; 16(1):84-100. PubMed ID: 33349222
[TBL] [Abstract][Full Text] [Related]
17. Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery.
Avgoustakis K
Curr Drug Deliv; 2004 Oct; 1(4):321-33. PubMed ID: 16305394
[TBL] [Abstract][Full Text] [Related]
18. Suitable carriers for encapsulation and distribution of endostar: comparison of endostar-loaded particulate carriers.
Chen W; Hu S
Int J Nanomedicine; 2011; 6():1535-41. PubMed ID: 21845043
[TBL] [Abstract][Full Text] [Related]
19. Controlled surface modification with poly(ethylene)glycol enhances diffusion of PLGA nanoparticles in human cervical mucus.
Cu Y; Saltzman WM
Mol Pharm; 2009; 6(1):173-81. PubMed ID: 19053536
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and characterization of tumor-targeted copolymer nanocarrier modified by transferrin.
Liu R; Wang Y; Li X; Bao W; Xia G; Chen W; Cheng J; Xu Y; Guo L; Chen B
Drug Des Devel Ther; 2015; 9():2705-19. PubMed ID: 26045659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
